# XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation

Source: https://onco.cc/trials/nct05275374/  
OnCo record `nct05275374` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of trametinib in colorectal cancer, run by Xynomic Pharmaceuticals, Inc., not yet recruiting.

## Summary

XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation is a phase 1/2, interventional study registered as NCT05275374 by Xynomic Pharmaceuticals, Inc., with a registry enrolment figure of 221 participants, started 2025-12-31 and due to reach its primary completion in 2027-12-30. Interventions recorded: XP-102; Trametinib. Conditions listed: Cancer; BRAF V600 Mutation; Melanoma; Colorectal Cancer; Thyroid Cancer; Nonsmall Cell Lung Cancer. Primary outcome: Characterize the safety of XP-102.; Evaluate the pharmacokinetics of XP-102.; Establish maximum tolerated dose of XP-102.. Colorectal eligibility wording from the registry: "* Advanced malignant solid tumor patients with a BRAF V600 mutation (limited to melanoma, colorectal cancer, non-small cell lung cancer, or thyroid cancer)". No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Also known as: ENHANCE
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT05275374
- Phase: 1/2
- Setting: A Dose-escalation and Expansion Phase I/IIa Study of XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation (ENHANCE)
- Sponsor: Xynomic Pharmaceuticals, Inc.
- Enrolled: 221

## Sources

- ClinicalTrials.gov NCT05275374: https://clinicaltrials.gov/study/NCT05275374

## Connected records

- cancers: [BRAF V600E-mutant colorectal cancer](https://onco.cc/cancers/braf-v600e-colorectal/), [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- drugs: [Trametinib](https://onco.cc/drugs/trametinib/)
- companies: [Xynomic Pharmaceuticals](https://onco.cc/companies/xynomic-pharmaceuticals/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct05275374.json